ESMO 2024 preview – Astellas’s KRAS degrader disappoints
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.